Top

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Systematic review update

Ocular adverse events from pharmacological treatment in patients with multiple sclerosis—A systematic review of the literature

Authors: Juliana Muñoz-Ortiz, Juliana Reyes-Guanes, Estefanía Zapata-Bravo, Laura Mora-Muñoz, Juan Antonio Reyes-Hurtado, Luis Octavio Tierradentro-García, William Rojas-Carabali, Marcela Gómez-Suarez, Alejandra de-la-Torre

Published in: Systematic Reviews | Issue 1/2021

Abstract

Purpose

The aim of this study was to review the scientific evidence and describe the ocular treatment-emergent adverse events (TEAEs) related to pharmacological treatment in patients with multiple sclerosis.

Methods

A systematic review of literature was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines in the MEDLINE, LILACS, EMBASE, and COCHRANE databases. Articles were filtered based on title and abstract considering the selection criteria and subsequently filtered by full-text reading. The resulting articles were evaluated using the Joanna Briggs Institute Quality Tools. Study characteristics and results were extracted and presented in structured tables to conduct a narrative synthesis.

Results

A total of 2852 published articles were extracted using our strategy. After removing duplicates, 2841 articles were screened based on title and abstract, 102 articles were evaluated using quality tools, and 69 articles were filtered by full-text reading. Through this search strategy, 60 articles met all the inclusion criteria and seven articles, through a search update conducted in the same manner, were included. This resulted in 67 articles meeting the inclusion criteria, of which 11 were experimental and 56 were observational. The therapies related to ocular TEAEs were alemtuzumab, amantadine, fingolimod, steroids, CTLA-4 Ig, estriol, interferon β, natalizumab, hyperbaric oxygen, rituximab, siponimod, teriflunomide, and tovaxin. Fingolimod and siponimod were commonly associated with macular edema, interferon β was associated with retinopathy, alemtuzumab was associated with thyroid eye disease, amantadine was associated with corneal edema, and steroids were associated with acute retinal necrosis. Opportunistic infections were also found, and there was one life-threatening case.

Conclusions

Our search revealed different methodological assessments of the topic. However, longitudinal studies regarding ocular TEAEs related to multiple sclerosis therapy are necessary to provide evidence-based recommendations, especially in understudied regions such as Latin America and Africa. Physicians should monitor ocular symptoms in patients being treated for multiple sclerosis and consider an interdisciplinary approach.

Systematic review registration

PROSPERO ID CRD42020106886

Available only for authorised users

Kantarci OH. Phases and phenotypes of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):636–54. https://doi.org/10.1212/CON.0000000000000737.CrossRefPubMed

Heath G, Airody A, Gale RP. The ocular manifestations of drugs used to treat multiple sclerosis. Drugs. 2017;77(3):303–11. https://doi.org/10.1007/s40265-017-0692-6.CrossRefPubMed

Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol. 2005;16(5):315–20. https://doi.org/10.1097/01.icu.0000179804.49842.e2.CrossRefPubMed

Safety Monitoring of Medicinal Products. Guidelines for setting up and running a Pharmacovigilance Centre. Uppsala Monitoring Centre - WHO Collaborating Centre for International Drug Monitoring, EQUUS, London, 2000. [Internet]. https://www.who.int/healthpromotion/about/HPG/en/. Accessed4 May 2020.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9. https://doi.org/10.1016/S0140-6736(00)02799-9.CrossRefPubMed

Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, W64. https://doi.org/10.7326/0003-4819-151-4-200908180-00135.CrossRefPubMed

Joanna Briggs Institute Global. EPB Resources & Publications | Joanna Briggs Institute. 2021. [online] Available at: https://jbi.global/ebp. Accessed 20 May 2021.

Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler. 2008;14(1):94–105. https://doi.org/10.1177/1352458507079658.CrossRefPubMed

Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–56. https://doi.org/10.1016/S1474-4422(14)70049-3. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

10.

Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010;362(5):402-415. [Internet]. https://www.nejm.org/doi/full/10.1056/NEJMoa0907839. Accessed 5 May 2020.

11.

Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler. 2012;18:843–52.CrossRef

12.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. https://doi.org/10.1016/S0140-6736(18)30475-6.CrossRefPubMed

13.

Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, Ogiwara K, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017;11:25–31. https://doi.org/10.1016/j.msard.2016.11.002.CrossRefPubMed

14.

Selmaj K, Li DKB, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67. https://doi.org/10.1016/S1474-4422(13)70102-9.CrossRefPubMed

15.

Vermersch P, Czlonkowska A, Grimaldi LME, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705–16. https://doi.org/10.1177/1352458513507821.CrossRefPubMed

16.

Voskuhl RR, Wang H, Wu TCJ, Sicotte NL, Nakamura K, Kurth F, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46. https://doi.org/10.1016/S1474-4422(15)00322-1.CrossRefPubMed

17.

Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008;71(12):917–24. https://doi.org/10.1212/01.wnl.0000325915.00112.61.CrossRefPubMed

18.

Pakdaman H, Abbasi M, Gharagozli K, Ashrafi F, Delavar Kasmaei H, Amini HA. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis. Neurol Sci. 2018;39(12):2107–13. https://doi.org/10.1007/s10072-018-3550-8.CrossRefPubMed

19.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021–33. https://doi.org/10.1016/S1474-4422(19)30238-8.CrossRefPubMed

20.

Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, et al. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013;131(1):103–7. https://doi.org/10.1001/jamaophthalmol.2013.570.CrossRefPubMed

21.

Akiyama H, Suzuki Y, Hara D, Shinohara K, Ogura H, Akamatsu M, Hasegawa Y. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report. Med (Baltim). 2016;95(29):e4180. https://doi.org/10.1097/MD.0000000000004180.

22.

Asensio-Sánchez VM, Trujillo-Guzmán L, Ramoa-Osorio R. Cystoid macular oedema after fingolimod treatment in multiple sclerosis. Arch Soc Esp Oftalmol. 2014;89(3):104–6. https://doi.org/10.1016/j.oftal.2012.07.020.CrossRefPubMed

23.

Bakri SJ, Swanson JW. Asymptomatic peripheral retinal hemorrhages as a manifestation of interferon beta 1a retinopathy. Semin Ophthalmol. 2015;30(1):56–7. https://doi.org/10.3109/08820538.2013.814693.CrossRefPubMed

24.

Bhatti MT, Freedman SM, Mahmoud TH. Fingolimod therapy and macular hemorrhage. J Neuroophthalmol. 2013;33(4):370–2. https://doi.org/10.1097/WNO.0b013e31829b42e1.CrossRefPubMed

25.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70(3):398–402. https://doi.org/10.1001/jamaneurol.2013.1960.CrossRefPubMed

26.

Christopher KL, Elner VM, Demirci H. Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis. Ophthal Plast Reconstr Surg. 2017;33(3):e73–5. https://doi.org/10.1097/IOP.0000000000000774.CrossRefPubMed

27.

Chui J, Herkes GK, Chang A. Management of fingolimod-associated macular edema. JAMA Ophthalmol. 2013;131(5):694–6. https://doi.org/10.1001/jamaophthalmol.2013.47.CrossRefPubMed

28.

de Massougnes S, Borruat FX, Ambresin A. Peripheral bilateral telangiectasiae in multiple sclerosis patients treated with interferon b1a. Klin Monbl Augenheilkd. 2016;233(4):438–40. https://doi.org/10.1055/s-0041-111803.CrossRefPubMed

29.

De Santi L, Costantini MC, Annunziata P. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren’s syndrome in a woman treated with interferon-beta. Acta Neurol Scand. 2005;112(3):194–6. https://doi.org/10.1111/j.1600-0404.2005.00455.x.CrossRefPubMed

30.

Esquenazi S. Bilateral reversible corneal edema associated with amantadine use. J Ocul Pharmacol Ther. 2009;25(6):567–70. https://doi.org/10.1089/jop.2009.0029.CrossRefPubMedPubMedCentral

31.

Gaetani L, Menduno PS, Cometa F, Di Gregorio M, Sarchielli P, Cagini C, et al. Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature. J Neurol. 2016;263(3):422–7. https://doi.org/10.1007/s00415-015-7879-0.CrossRefPubMed

32.

Gallego-Pinazo R, España-Gregori E, Casanova B, Pardo-López D, Díaz-Llopis M. Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis. J Neuroophthalmol. 2011;31(3):292–3. https://doi.org/10.1097/WNO.0b013e31822bed20.CrossRefPubMed

33.

Fan Gaskin JC-C, Coote M. Postoperative cystoid macular oedema in a patient on fingolimod. BMJ Case Rep. 2015;2015(may12 1):bcr2015210415. https://doi.org/10.1136/bcr-2015-210415.CrossRefPubMedCentral

34.

Jasani KM, Sharaf N, Rog D, Aslam T. Fingolimod-associated macular oedema. BMJ Case Rep. 2017;2017:bcr-2016. https://doi.org/10.1136/bcr-2016-218912.CrossRef

35.

Jeng BH, Galor A, Lee MS, Meisler DM, Hollyfield JG, Schoenfield L, et al. Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. Ophthalmology. 2008;115(9):1540–4. https://doi.org/10.1016/j.ophtha.2008.03.011.CrossRefPubMed

36.

Jenisch T, Dietrich-Ntoukas T, Renner AB, Helbig H, Gamulescu MA. Combined retinal artery and vein occlusions associated with interferon beta therapy. Ophthalmologe. 2012;109(1):71–5. https://doi.org/10.1007/s00347-011-2448-0.CrossRefPubMed

37.

Kim MJ, Bhatti MT, Costello F. Famous. Surv Ophthalmol. 2016;61(4):512–9. https://doi.org/10.1016/j.survophthal.2015.12.008.CrossRefPubMed

38.

Lambrou GN, Kopferschmitt J, Jaeger A, Brini A. Slowly reversible central scotoma: iatrogenic effect of hyperbaric oxygenation in the treatment of multiple sclerosis. J Fr Ophtalmol. 1987;10(1):51–9.PubMed

39.

Longmuir R, Lee AG, Rouleau J. Cotton wool spots associated with interferon beta-1 alpha therapy. Semin Ophthalmol. 2007;22(1):49–53. https://doi.org/10.1080/08820530601182725.CrossRefPubMed

40.

Mallada-Frechín J, Abellán-Miralles I, Alfaro-Beltra ML, Medrano V, Muñoz-Gil MB, Fernández-Izquierdo S, et al. Retinopathy secondary to treatment with interferon beta-1a in a patient with multiple sclerosis. Rev Neurol. 2005;40(8):482–4. https://doi.org/10.33588/rn.4008.2005132.CrossRefPubMed

41.

Minuk A, Belliveau MJ, Almeida DRP, Dorrepaal SJ, Gale JS. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use. JAMA Ophthalmol. 2013;131(6):802–4. https://doi.org/10.1001/jamaophthalmol.2013.2465.CrossRefPubMed

42.

Ohira M, Ito D, Shimizu T, Shibata M, Ohde H, Suzuki N. Retinopathy: an overlooked adverse effect of interferon-beta treatment of multiple sclerosis. Keio J Med. 2009;58(1):54–6. https://doi.org/10.2302/kjm.58.54.CrossRefPubMed

43.

Post JW, Colleaux K. Interferon beta retinopathy in a patient with multiple sclerosis. Can J Ophthalmol. 2009;44(5):e37. https://doi.org/10.3129/i09-094.CrossRefPubMed

44.

Pul R, Osmanovic A, Schmalstieg H, Pielen A, Pars K, Schwenkenbecher P et al. Fingolimod associated bilateral cystoid macular edema—wait and see? [Internet]. Int J Mol Sci. 2016;17(12) https://doi.org/10.3390/ijms17122106.

45.

Saatci AO, Ayhan Z, Arikan G, Sayiner A, Ada E. Unilateral acute retinal necrosis in a multiple sclerosis patient treated with high-dose systemic steroids. Int Ophthalmol. 2010;30(5):629–32. https://doi.org/10.1007/s10792-010-9380-1.CrossRefPubMed

46.

Saito H, Suzuki M, Asakawa T, Kato S. Retinopathy in a multiple sclerosis patient undergoing interferon-therapy. Mult Scler. 2007;13(7):939–40. https://doi.org/10.1177/1352458507077403.CrossRefPubMed

47.

Sallansonnet-Froment M, Roux X, de Greslan T, Bounolleau P, Taillia H, Ricard D, et al. Interferon-beta retinopathy. Rev Neurol (Paris). 2009;165(11):971–4. https://doi.org/10.1016/j.neurol.2008.11.019.CrossRef

48.

Schröder K, Finis D, Harmel J, Ringelstein M, Hartung HP, Geerling G, et al. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Mult Scler Relat Disord. 2015;4(5):406–8. https://doi.org/10.1016/j.msard.2015.06.015.CrossRefPubMed

49.

Sheikh Z, Jain S, Hillen M. Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge! Neurology. 2016;86(10):972–3. https://doi.org/10.1212/WNL.0000000000002450.CrossRefPubMedPubMedCentral

50.

Sommer S, Sablon JC, Zaoui M, Rozot P, Hosni A. Interferon beta-1b retinopathy during a treatment for multiple sclerosis. J Fr Ophtalmol. 2001;24(5):509–12.PubMed

51.

Spierer O, Leibovitch I. Recurrent orbital inflammation in a patient with multiple sclerosis treated with interferon-beta. Clin Exp Ophthalmol. 2011;39(8):835–7. https://doi.org/10.1111/j.1442-9071.2011.02549.x.CrossRefPubMed

52.

Thoo S, Cugati S, Lee A, Chen C. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler. 2015;21(2):249–51. https://doi.org/10.1177/1352458514528759.CrossRefPubMed

53.

Trinh T, Haridas AS, Sullivan TJ. Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease. Ophthal Plast Reconstr Surg. 2016;32(6):e128–9. https://doi.org/10.1097/IOP.0000000000000310.CrossRefPubMed

54.

Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema? J Neurol. 2012;259(2):386–8. https://doi.org/10.1007/s00415-011-6367-4.CrossRefPubMed

55.

Ueda N, Saida K. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmol. 2015;15(1):135. https://doi.org/10.1186/s12886-015-0125-9.CrossRefPubMedPubMedCentral

56.

Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology. 2009;73(17):1418–9. https://doi.org/10.1212/WNL.0b013e3181bd114f.CrossRefPubMed

57.

Cifuentes-Canorea P, Nieves-Moreno M, Sáenz-Francés F, Santos-Bueso E. Edema macular precoz y recurrente en paciente en tratamiento con fingolimod. Neurología. 2019;34(3):206–7. https://doi.org/10.1016/j.nrl.2016.08.005.CrossRefPubMed

58.

Husmann R, Davies JB, Ghannam M, Berry B, Kelkar P. Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications. Clin Mol Allergy. 2020;18(1):3. https://doi.org/10.1186/s12948-020-00119-4.CrossRefPubMedPubMedCentral

59.

Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC. Graves’ disease after treatment with alemtuzumab for multiple sclerosis. Hormones (Athens). 2015;14(1):148–53. https://doi.org/10.14310/horm.2002.1501.CrossRef

60.

Williams KE, Johnson LN. Neuroretinitis in patients with multiple sclerosis. Ophthalmology. 2004;111(2):335–40; discussion 340-1. https://doi.org/10.1016/S0161-6420(03)00663-8.CrossRefPubMed

61.

Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series. Eye (Lond). 2019;33(2):223–9. https://doi.org/10.1038/s41433-018-0282-1.CrossRefPubMed

62.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17(6):708–19. https://doi.org/10.1177/1352458510394701.CrossRefPubMed

63.

Lapierre Y, O’Connor P, Devonshire V, Freedman MS, Kremenchutzky M, Yeung M, et al. Canadian experience with fingolimod: adherence to treatment and monitoring. Can J Neurol Sci. 2016;43(2):278–83. https://doi.org/10.1017/cjn.2015.325.CrossRefPubMed

64.

Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, et al. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurol Sci. 2017;38(1):53–9. https://doi.org/10.1007/s10072-016-2701-z.CrossRefPubMed

65.

Liscić RM, Brecelj J. Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a. Croat Med J. 2004;45(3):323–7.PubMed

66.

Makioka H, Nakaya F, Ling Y, Torii S, Saida T, Kira JI. Safety and effectiveness of interferon β-1a intramuscular therapy: results of the postmarketing drug surveillance in Japan. Rinsho Shinkeigaku. 2017;57(10):553–61. https://doi.org/10.5692/clinicalneurol.cn-001074.CrossRefPubMed

67.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323(1–2):167–72. https://doi.org/10.1016/j.jns.2012.09.009.CrossRefPubMedPubMedCentral

68.

Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). J Neuroimmune Pharmacol. 2016;11(1):1–8 https://doi.org/10.1007/s11481-015-9646-5, 1.

69.

Smith MY, Sabidó-Espin M, Trochanov A, Samuelson M, Guedes S, Corvino FA, et al. Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: A retrospective administrative claims analysis. J Manag Care Spec Pharm. 2015;21(8):650–60. https://doi.org/10.18553/jmcp.2015.21.8.650.CrossRefPubMed

70.

Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208–15. https://doi.org/10.1136/jnnp-2014-307721.CrossRefPubMed

71.

Weglinski L, Manceau P, Thomas-Pohl M, Le Breton F, Amarenco G. Prospective evaluation of mouth and eye dryness induced by antimuscarinic drugs used for neurogenic overactive bladder in 35 patients with multiple sclerosis. Prog Urol. 2017;27(4):253–60. https://doi.org/10.1016/j.purol.2016.10.005.CrossRefPubMed

72.

Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler. 2016;22(9):1215–23. https://doi.org/10.1177/1352458515614092.CrossRefPubMed

73.

Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120(7):1432–9. https://doi.org/10.1016/j.ophtha.2012.12.040.CrossRefPubMed

74.

Gugliandolo A, Longo F, Marrosu MG, Mancardi GL, Gandoglia I, Melis M, et al. A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients [Internet]. Ther Clin Risk Manag. 2018;14:1765–88. https://doi.org/10.2147/TCRM.S174864.CrossRefPubMedPubMedCentral

75.

Fruschelli M, Capozzoli M, Gelmi MC, Masi G, Annunziata P. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing–remitting multiple sclerosis. Int Ophthalmol. 2019;39(4):777–81. https://doi.org/10.1007/s10792-018-0870-x.CrossRefPubMed

76.

Lim LL, Silva DG, Lo TC, Pimentel RS, Butzkueven H, Hall AJ. Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: incidence, prevalence, and impact on disease course. Ophthalmology. 2019;126(3):438–44. https://doi.org/10.1016/j.ophtha.2018.10.013.CrossRefPubMed

77.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (sunbeam): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009–20. https://doi.org/10.1016/S1474-4422(19)30239-X.CrossRefPubMed

78.

Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag. 2009;5(3):585–94. https://doi.org/10.2147/tcrm.s5218.CrossRefPubMedPubMedCentral

79.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. https://doi.org/10.1056/NEJMoa044397.CrossRefPubMed

80.

Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. https://doi.org/10.1136/bmj.i157.CrossRefPubMed

81.

Peryer G, Golder S, Junqueira D, Vohra S, Loke YK. Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from https://www.training.cochrane.org/handbook.

82.

Management Sciences for Health and World Health Organization. Drug and Therapeutics Committee Training Course. Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program. Arlington: Management Sciences for Health; 2007.

83.

Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157–69. https://doi.org/10.1016/S1474-4422(11)70274-5.CrossRefPubMed

84.

Frohman TC, Graves J, Balcer LJ, Galetta SL, Frohman EM. The neuro-ophthalmology of multiple sclerosis. Continuum (Minneap Minn). 2010;16(5 Multiple Sclerosis):122–46 https://doi.org/10.1212/01.CON.0000389938.07532.67.

85.

Bomprezzi R, Powers JM. IFN-β1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. 2020. Accessed 5 May 2020. https://n.neurology.org/content/ifn%CE%B2-1b-may-severely-exacerbate-japanese-optic-spinal-ms-neuromyelitis-optica-spectrum.

86.

Pula JH, Reder AT. Multiple sclerosis. Part I: Neuro-ophthalmic manifestations. Curr Opin Ophthalmol. 2009;20(6):467–75. https://doi.org/10.1097/ICU.0b013e328331913b.CrossRefPubMed

87.

Andrew L. Ophthalmic screening recommendation for new MS drug. [online] The Ophthalmic News and Education Network. 2018. Available at: https://www.aao.org/editors-choice/ophthalmic-screening-recommendation-new-ms-drug. Accessed 20 May 2021.

88.

Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest. 1988;11(8):615–9. https://doi.org/10.1007/BF03350193.CrossRefPubMed

89.

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709–17.[Editor1]. https://doi.org/10.1080/14740338.2018.1483330.CrossRefPubMed

Title: Ocular adverse events from pharmacological treatment in patients with multiple sclerosis—A systematic review of the literature
Authors: Juliana Muñoz-Ortiz
Juliana Reyes-Guanes
Estefanía Zapata-Bravo
Laura Mora-Muñoz
Juan Antonio Reyes-Hurtado
Luis Octavio Tierradentro-García
William Rojas-Carabali
Marcela Gómez-Suarez
Alejandra de-la-Torre
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Multiple Sclerosis
Edema
Fingolimod
Teriflunomide
Alemtuzumab
Siponimod
Amantadine
Alemtuzumab
Estriol
Published in: Systematic Reviews / Issue 1/2021
Electronic ISSN: 2046-4053
DOI: https://doi.org/10.1186/s13643-021-01782-7

At a glance: The STEP trials

Springer Medicine

Ocular adverse events from pharmacological treatment in patients with multiple sclerosis—A systematic review of the literature

Abstract

Purpose

Methods

Results

Conclusions

Systematic review registration

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Systematic review registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Evidence for implementation of interventions to promote mental health in the workplace: a systematic scoping review protocol

Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol

Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials

A characterization of cortisol level and adrenal reservation in human cardiopulmonary arrest: systematic review and meta-analysis

Enrollment, retention, and strategies for including disadvantaged populations in randomized controlled trials: a systematic review protocol

Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality